METXCHEM/BME 170/270
Case Study Instructions
Spring 2014
Students will work in collaborative teams to develop and present three case studies (80
pts each; 30 oral + 50 written).
1. Student teams will orally present their case study on Tue or Thursday ( 20 – 25 min.
total, including time for questions), and submit a written summary of each drug/case
within 2 days of presenting the case.
o Oral presentations will be peer-reviewed within class
o The written summary should be 3 – 4 pages of text maximum, excluding
figures and tables. Place all figures and tables at the end of the document,
using complete captions, etc.
o The written summary also should include a brief written statement of each
student’s specific contribution to the case report.
2. Individual case studies will focus on a particular diseases/health condition.
o Student teams will select a specific drug currently or historically used in the
treatment of the selected disease/health condition.
o Students in each team should reach consensus on the disease/drug topic and
inform the instructor at least 1 week prior to presenting case.
3. For each case, the team will select a key scientific paper for assignment to the class
to read before the case is presented; the selected paper must be approved by the
instructor before assigning to the class. The paper can reflect outcomes of
experimental or clinical evidence leading to FDA approval, post marketing
surveillance, published data reporting efficacy or adverse reactions, etc.
4. Oral and written presentation of the the case/drug should include the following
components when appropriate to the case:
1) Drug chemical properties,
2) Molecular target(s),
3) Background of discovery / development
4) Summary of experimental and clinical evidence in patent that supports drug
action and efficacy
5) Adverse reactions and contraindications.
6) Post-marketing surveillance evidence (clinical and experimental scientific
literature) on efficacy / adverse effects
7) Specific discussion of at least some elements of the assigned paper.
8) The group may develop additional novel aspects of the drug development /
assessment process to build on intellectual strengths or interests of group
members.
METXCHEM/BME 170/270
Case Study Instructions
Spring 2014
Case Study Group Assignments:
25 min total/grp = 20 min pre + 5 min questions
Case study #1
Tue April 15th, groups 1, 2, 4
Thur April 17th, groups 3, 5, 6
Case study #2
Tue May 6th , groups 3, 5, 6
Thur May 8th , groups 1, 2, 4
Case study #3
Tue June 3rd , groups 2, 3, 5
Thur June 5th , groups 1, 4, 6
Group
Group Group
Assignm
Assignm Assignm
ent
ent CS 1 ent CS 2
CS 3
Dept
First Name
Last Name
Level
Email Address
BME 170
Corrigan
Horton
Senior
cahorton@ucsc.edu
6
5
4
Chem 170
Erika
Lucas
Senior
ellucas@ucsc.edu
4
6
5
Chem 170
Marshall
Porter
Senior
mwporter@ucsc.edu
5
4
6
Metx 170
Bader
Nasir
Senior
bnasir@ucsc.edu
4
5
6
Metx 170
Grinpal
Singh
Senior
gsingh11@ucsc.edu
5
6
4
Metx 170
Lauren
Ysais
Senior
lysais@ucsc.edu
6
4
6
Metx 170
Glenn
Geeseman
ConEnrol
gjgbull@gmail.com
6
6
5
BME 270
Thomas
Busch
Graduate
tbusch@ucsc.edu
1
2
3
BME 270
Chem 270
Chem 270
John
Valerie
Kathleen
Collins
Chen
Markham
Graduate
Graduate
Graduate
jopacoll@ucsc.edu
kaamarkh@ucsc.edu
2
2
3
3
1
2
1
3
1
Metx 270
Jessica
Morgan
Graduate
jemmorga@ucsc.edu
3
1
2
Updated April 28th, 2014
vchen2@ucsc.edu